“We concluded 2023 by dosing the first patients in our two Phase 3 SYNCHRONY studies evaluating EFX in the treatment of patients with pre-cirrhotic MASH,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “In the first half of 2024, we look forward to reporting results from the second on-treatment biopsy in our 96-week Phase 2b HARMONY study in patients with pre-cirrhotic MASH and initiating our third Phase 3 SYNCHRONY study in patients with cirrhosis due to MASH.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKRO:
- Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Madrigal opportunity in MASH remains after Boehringer data, says UBS
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- Akero Therapeutics management to meet with Cantor Fitzgerald
